BetterLife Pharma's CEO is Ahmad Doroudian, appointed in Jan 2020, has a tenure of 6.42 years. total yearly compensation is CA$328.71K, comprised of 91.3% salary and 8.7% bonuses, including company stock and options. directly owns 10.31% of the company’s shares, worth $796.50K. The average tenure of the management team and the board of directors is 3.1 years and 4.4 years respectively.
Key information
Ahmad Doroudian
Chief executive officer
CA$328.7k
Total compensation
CEO salary percentage
91.27%
CEO tenure
6.4yrs
CEO ownership
10.3%
Management average tenure
3.1yrs
Board average tenure
4.4yrs
Recent management updates
Recent updates
CEO Compensation Analysis
How has Ahmad Doroudian's remuneration changed compared to BetterLife Pharma's earnings?
Date
Total Compensation
Salary
Company Earnings
Jan 31 2026
CA$329k
CA$300k
-CA$1m
Oct 31 2025
n/a
n/a
-CA$2m
Jul 31 2025
n/a
n/a
-CA$840k
Apr 30 2025
n/a
n/a
-CA$2m
Jan 31 2025
CA$683k
CA$300k
-CA$4m
Oct 31 2024
n/a
n/a
-CA$4m
Jul 31 2024
n/a
n/a
-CA$5m
Apr 30 2024
n/a
n/a
-CA$4m
Jan 31 2024
CA$440k
CA$300k
-CA$3m
Oct 31 2023
n/a
n/a
-CA$2m
Jul 31 2023
n/a
n/a
-CA$6m
Apr 30 2023
n/a
n/a
-CA$6m
Jan 31 2023
CA$300k
CA$300k
-CA$9m
Oct 31 2022
n/a
n/a
-CA$12m
Jul 31 2022
n/a
n/a
-CA$10m
Apr 30 2022
n/a
n/a
-CA$13m
Jan 31 2022
CA$300k
CA$300k
-CA$12m
Oct 31 2021
n/a
n/a
-CA$36m
Jul 31 2021
n/a
n/a
-CA$41m
Apr 30 2021
n/a
n/a
-CA$39m
Jan 31 2021
CA$160k
CA$160k
-CA$36m
Oct 31 2020
n/a
n/a
-CA$20m
Jul 31 2020
n/a
n/a
-CA$15m
Apr 30 2020
n/a
n/a
-CA$18m
Jan 31 2020
CA$176k
CA$176k
-CA$20m
Compensation vs Market: Ahmad's total compensation ($USD232.00K) is below average for companies of similar size in the US market ($USD640.99K).
Compensation vs Earnings: Ahmad's compensation has been consistent with company performance over the past year.
CEO
Ahmad Doroudian (66 yo)
6.4yrs
Tenure
CA$328,707
Compensation
Dr. Ahmad Doroudian, Ph D., is Founder of BetterLife Pharma Inc. and serves as Chief Executive Officer and served as Interim Chief Executive Officer. He serves as Director at BetterLife Pharma Inc. since J...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Ahmad Doroudian
Founder
6.4yrs
CA$328.71k
10.31% $ 796.5k
Moira Ong
Chief Financial Officer
15.5yrs
CA$292.71k
1.01% $ 78.2k
Hooshmand Sheshbaradaran
Chief Operating Officer
3.1yrs
CA$404.76k
4.26% $ 329.2k
Stephen Sangha
Corporate Development Advisor & Director
3yrs
CA$40.28k
15.77% $ 1.2m
Douglas Drysdale
Executive Chairman & Member of Scientific Advisory Board
1.4yrs
no data
0.93% $ 72.0k
Scott Rudge
Head of CMC
no data
no data
no data
3.1yrs
Average Tenure
61yo
Average Age
Experienced Management: BETR.F's management team is considered experienced (3.1 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Ahmad Doroudian
Founder
6.4yrs
CA$328.71k
10.31% $ 796.5k
Stephen Sangha
Corporate Development Advisor & Director
1.3yrs
CA$40.28k
15.77% $ 1.2m
Douglas Drysdale
Executive Chairman & Member of Scientific Advisory Board
1.4yrs
no data
0.93% $ 72.0k
Ralph Pullen
Independent Director
6.1yrs
CA$49.37k
0.11% $ 8.8k
Daniel Carcillo
Member of Scientific Advisory Board
1.4yrs
no data
no data
John McCorvy
Member of Scientific Advisory Board
4.4yrs
no data
no data
Adam Halberstadt
Member of Scientific Advisory Board
4.4yrs
no data
no data
Argel Aguilar-Valles
Member of Scientific Advisory Board
4.4yrs
no data
no data
4.4yrs
Average Tenure
61yo
Average Age
Experienced Board: BETR.F's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/22 18:06
End of Day Share Price
2026/06/22 00:00
Earnings
2026/01/31
Annual Earnings
2026/01/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BetterLife Pharma Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.